Lucira Health (LHDXQ) Stock Price, News & Analysis

Company Overview

Lucira Health, Inc. was a medical diagnostics company focused on developing rapid, at-home molecular testing products for infectious diseases. Its best-known product was the Lucira COVID-19 All-In-One Test, a single-use molecular test designed to detect the virus from a nasal swab and deliver results without requiring a laboratory.

The Lucira COVID-19 test received emergency use authorization from the U.S. Food and Drug Administration in 2020 and was marketed in the United States through healthcare providers, retail channels and direct-to-consumer sales. The company also pursued additional testing applications, including products intended to identify influenza alongside COVID-19, although its commercial operations were primarily associated with COVID-19 diagnostics.

Lucira Health was headquartered in Emeryville, California, and served the U.S. market. In February 2023, the company filed for protection under Chapter 11 of the U.S. Bankruptcy Code after reporting that it could not secure sufficient financing to continue operating. Pfizer subsequently acquired substantially all of Lucira Health’s assets through the bankruptcy process. As a result, Lucira Health’s operations and product availability should be viewed primarily in a historical context.

Key Stats

• Today's Range: $0.0001 to $0.0001
• 50-Day Range: N/A
• 52-Week Range: $0.00 to $1.45
• Volume: 20,900 shs
• Average Volume: 7.18 million shs
• Market Capitalization: $4.06 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 11/11/2021
• Today: 9/22/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Diagnostic substances
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:LHDXQ
• CIK: 1652724
• Web: www.lucirahealth.com
• Phone: 510-350-8071
• Fax: N/A
• Employees: 221
• Year Founded: 2013

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $93.06 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.81 per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 40,600,000
• Free Float: 28,257,000
• Market Cap: $4.06 thousand
• Optionable: Not Optionable
• Beta: 2.60